Table 3.

Sensitivity Analyses for Concurrent Within-Individual Associations

Sensitivity Analysis	Patients (n)	Substance-Related Events (n)	Unadjusted		Adjusted
			OR	(95% CI)	OR	(95% CI)
Male
One-month-extended medicated periods	1,579,704	46,676	0.82	(0.80–0.84)	0.67	(0.66–0.69)
Stimulant medication only	1,579,704	46,676	0.80	(0.78–0.82)	0.66	(0.64–0.68)
Ambulance, inpatient, or emergency events	1,579,704	80,653	0.77	(0.76–0.79)	0.71	(0.69–0.72)
Agea
13–17	615,297	18,410	0.69	(0.66–0.72)	0.61	(0.59–0.64)
18–25	366,021	15,566	0.97	(0.92–1.01)	0.77	(0.74–0.81)
26–35	236,249	4,961	0.81	(0.74–0.88)	0.57	(0.52–0.63)
36–45	174,849	3,690	0.77	(0.70–0.86)	0.62	(0.56–0.69)
46+	187,288	4,049	0.69	(0.62–0.76)	0.55	(0.49–0.61)
SSRI medication	1,579,704	46,676	1.34	(1.30–1.39)	1.42	(1.37–1.47)
Female
One-month-extended medicated periods	1,414,183	31,842	0.90	(0.87–0.93)	0.74	(0.71–0.76)
Stimulant medication only	1,414,183	31,842	0.85	(0.82–0.88)	0.70	(0.68–0.72)
Ambulance, inpatient, or emergency events	1,414,183	54,420	0.79	(0.77–0.81)	0.71	(0.69–0.73)
Agea
13–17	299,018	8,714	0.85	(0.80–0.90)	0.77	(0.73–0.82)
18–25	333,016	9,767	0.98	(0.93–1.04)	0.78	(0.74–0.83)
26–35	266,275	4,485	0.80	(0.74–0.88)	0.60	(0.55–0.65)
36–45	241,620	4,384	0.67	(0.61–0.73)	0.54	(0.50–0.60)
46+	274,254	4,492	0.72	(0.66–0.79)	0.56	(0.51–0.62)
SSRI medication	1,414,183	31,842	1.22	(1.18–1.27)	1.25	(1.20–1.30)

Note. Adjusted models control for time since last substance-related event. ADHD = attention-deficit/hyperactivity disorder. OR = odds ratio. SSRI = selective serotonin reuptake inhibitor.

^aAge group in years at start of follow-up.